JAK3 and psoriasis: ASP015 K, a selective JAK3 inhibitor, has undergone a phase IIa dose escalation study (NCT01096862) in a cohort of 124 patients with moderate-to-severe psoriasis (see http://www.clinicaltrials.gov).